{'fraction_non_alphanumeric': 0.04139715394566624, 'fraction_numerical': 0.03040103492884864, 'mean_word_length': 4.904580152671755, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Dose‐dependent antiviral activity of released‐active form of antibodies to interferon‐gamma against influenza A/California/07/09(H1N1) in murine model

The assessment of dose–response is an essential part of drug development in terms of the determination of a drug's effective dose, finding the safety endpoint, estimation of the pharmacokinetic profile, and even validation of drug activity, especially for therapeutic agents with a principally novel mechanism of action. Drugs based on released‐active forms of antibodies are a good example of such a target. In this study, the efficacy of the antiviral drug Anaferon for children (released‐active form of antibodies to interferon‐gamma) was tested in a dose‐dependent manner (at doses of 0.13, 0.2, 0.4, 0.8 ml/mouse/day) in a murine model of acute pneumonia induced by influenza virus pandemic strain A/California/07/09 (H1N1). Administration of the drug at the two highest doses led to: a reduction in the virus infectious titer in lung tissue up to 4.2 lgEID50/20 mg of tissue; infected animals’ life prolongation up to 6.7 days; an increase in the survival rate of up to 40% and a decrease in morphological signs of inflammation when compared to the control animals. In this study, the dose–response effect of Anaferon for Children was demonstrated on mice for the first time. This finding is especially important for drugs with a principally novel mechanism of action like drugs based on released‐active forms of antibodies. J. Med. Virol. 89:759–766, 2017. © 2016 Wiley Periodicals, Inc.